For TIO, change
can begin within1,2
CRYSVITA is the only treatment that targets the cause of FGF23-related hypophosphatemia in TIO
FGF23=fibroblast growth factor 23; TIO=tumor-induced osteomalacia.
Actor portrayal
Learn about two phase 2 studies that demonstrated how CRYSVITA helped increase serum phosphorus levels and helped heal osteomalacia1,3
CRYSVITA®(burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
![](/tio/images/home-page/png/lg/learn-bg.png)
![](/tio/images/global/png/black-left.png)
Ready to start your patients on CRYSVITA?
Take the first step by filling out the enrollment form.
![](/tio/images/global/png/black-right.png)